Previous 10 | Next 10 |
Gainers: [[MDWD]] +19.5%. [[KZR]] +14.3%. [[PQG]] +9%. [[GOSS]] +4%. [[RC]] +2.6%.Losers: [[MESO]] -7.6%. [[CELP]] -5.3%. [[GDS]] -5.1%. [[EAF]] -4.2%. [[RUBY]] -4%. For further details see: MESO, EAF, RC and MDWD among after-hours movers
NEW YORK, Dec. 14, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced top-line results from the landmark DREAM-HF Phase 3 randomized controlled trial of its allogeneic cell therapy rexl...
NEW YORK, Dec. 14, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast today to provide a corporate update. The webcast will begin at 9.00am AEDT, Tuesday, December 15; 5.00pm ...
NEW YORK, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced results presented at the 62 nd annual meeting American Society of Hematology (ASH), which provid...
Tredegar Corporation (TG +29% on declaring special dividend.Catabasis Pharmaceuticals (CATB) +25%.India Globalization Capital (IGC) +19%.Ashford Hospitality Trust (AHT) +14%.Mesoblast Limited (MESO) +12%.iBio (IBIO +12% after company was selected to produce ATB Therapeutic...
The FDA designates Mesoblast Limited's (MESO) Phase 3-stage Ryoncil (remestemcel-L) for Fast Track review for the treatment of acute respiratory distress syndrome ((ARDS)) due to COVID-19.Fast Track status provides for more frequent interaction with the FDA review team and a rolling review of...
NEW YORK, Dec. 02, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that the United States Food and Drug Administration (FDA) has granted Fast Track designation for remestemcel-L in t...
Gainers: [[TG]] +29.6%. [[MESO]] +11.8%. [[FUBO]] +10.5%. [[VAPO]] +9.2%. [[SLQT]] +6.5%.Losers: [[OVID]] -48.7%. [[FCEL]] -16.8%. [[IRTC]] -16.1%. [[SOL]] -13.2%. [[RETA]] -9.1%. For further details see: TG, OVID, FCEL and MESO among after-hours movers
Image source: The Motley Fool. Mesoblast (NASDAQ: MESO) Q1 2021 Earnings Call Nov 19, 2020 , 5:00 p.m. ET Operator Continue reading For further details see: Mesoblast (MESO) Q1 2021 Earnings Call Transcript
BIO-key International (BKYI) +44% after partnering with Prominic.NET.Ideanomics (IDEX) +33% after increasing stake in e-Tractor company.Kaixin Auto Holdings (KXIN) +32%.DPW Holdings (DPW) +29% after entering new franchise program.CPS Technologies Corporation (CPS...
News, Short Squeeze, Breakout and More Instantly...
2024-07-23 14:15:03 ET Piper Sandler analyst issues OVERWEIGHT recommendation for MESO on July 23, 2024 12:57PM ET. MESO was trading at $8.29 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 5 - Buy, 2 - H...
NEW YORK, July 23, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced that the United States Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) resubmission for...
NEW YORK, July 21, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced today that the confirmatory Phase 3 trial of its allogeneic, immunoselected, and industrially manufactured stromal cell product...